Insulet Corporation
Financials
Valuation Metrics
Insulet Corporation's Market Cap is $10.65B. At end of 2025 it was $20.00B. Ranked #885 of 3,118 in US market (top 28%), #274 of 1,474 on NASDAQ (top 19%), #65 of 203 in Health Care Equipment & Services (top 32%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $10.65B | US#885/3,118 Sec#65/203 |
| Revenue | $3.05B | US#1,173/3,118 Sec#71/203 |
| Net Income | $375M | US#979/3,118 Sec#53/203 |
| Total Assets | $3.17B | US#1,774/3,118 Sec#85/203 |
| Net Assets | $1.42B | US#1,503/3,118 Sec#78/203 |
| Employees | 5,400 | US#1,187/3,118 Sec#87/203 |
| Value | ||
| P/E | 28.36x | US#1,498/3,118 Sec#53/203 |
| P/B | 7.49x | US#2,473/3,118 Sec#155/203 |
| PEG | 0.48x | US#574/3,118 Sec#22/203 |
| P/S | 3.49x | US#1,889/3,118 Sec#127/203 |
| EV/EBITDA | 17.36x | US#1,719/3,118 Sec#73/203 |
| FCF Yield | 2.80% | US#1,844/3,118 Sec#106/203 |
| Profitability | ||
| ROE | 26.39% | US#376/3,118 Sec#18/203 |
| ROA | 11.86% | US#358/3,118 Sec#20/203 |
| Op. Margin | 16.89% | US#1,073/3,118 Sec#37/203 |
| Revenue Growth | 29.41% | US#431/3,118 Sec#27/203 |
| Earnings Growth | 58.96% | US#435/3,118 Sec#21/203 |
| Financial Health | ||
| Debt Ratio | 122.55% | US#1,270/3,118 Sec#123/203 |
| Total Debt | $948M | US#1,545/3,118 Sec#84/203 |
| FCF | $298M | US#1,169/3,118 Sec#69/203 |
| Cash | $535M | US#1,028/3,118 Sec#58/203 |
| Current Ratio | 2.48x | US#964/3,118 Sec#97/203 |
| Net Debt/EBITDA | 0.65x | US#830/3,118 Sec#51/203 |
| Performance | ||
| 1Y Return | -50.90% | US#2,891/3,118 Sec#188/203 |
| 1M Return | 16.71% | US#448/3,118 Sec#37/203 |
| From 52W High | -56.69% | US#2,795/3,118 Sec#188/203 |
| 1Y MDD | -62.33% | US#2,777/3,118 Sec#175/203 |
| Trading | ||
| Volume | 1,256,384 shares | US#1,697/3,118 Sec#119/203 |
| Trading Value | $192M | US#799/3,118 Sec#65/203 |
| Per Share | ||
| EPS | $5.42 | US#625/3,118 Sec#39/203 |
| BPS | $20.53 | US#1,211/3,118 Sec#69/203 |
Company Info
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.